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EDITORIAL
Chemoradiotherapy in Esophageal Cancer
Toxicity is in the Eye of the Beholder
David H. Ilson, MD, PhD
Dr. Murthy and colleagues report, in this issue of the Journal of Thoracic Oncology,potential long-term complications in patients undergoing preoperative chemoradiother-
apy for esophageal cancer.1 They compared patients treated with preoperative chemoradio-
therapy to a group of patients undergoing esophagectomy alone at the Cleveland Clinic. They
report that the use of preoperative chemoradiotherapy led to an increased rate of late pleural
and pericardial effusions. Despite this observation, there was no significant increase in the need
for intervention to treat these complications, and there was no adverse impact on patient survival.
The use of preoperative chemoradiotherapy in esophageal cancer has evolved as a
therapy standard at most cancer centers in the United States. Although there are not clear cut
phase III data to indicate a survival benefit for this approach compared with surgery alone,
individual trials generally have been small and underpowered. Nearly all trials indicate trends
toward improved survival with the use of preoperative chemoradiotherapy, in particular in
patients achieving a pathologic complete response. Meta-analyses also support a survival
benefit for preoperative chemoradiotherapy.2 A recent phase III trial from Germany indicated
strong trends for superior survival and local tumor control for the use of combined preoper-
ative chemoradiotherapy compared with preoperative chemotherapy alone, in high risk
patients staged T3 or T4 with endoscopic ultrasound and laparoscopy.3 Although collectively
the published literature indicates a survival benefit for combined preoperative chemoradiotherapy,
the absolute survival improvements ranging from 10 to 20% are modest at best. As the authors
indicate in their current series, this potential modest improvement in survival may come at the
cost of an increase in potential late complications.
Is toxicity of all chemoradiotherapy comparable? Most series report only short-term
perioperative complications after combined chemoradiotherapy and indicate the approach
is safe and tolerable. However, toxicity is also likely to vary by the chemotherapy
regimen, dose, and schedule, as well as the dose and fractionation schedule of radiother-
apy. The authors in the current series either used intermittent, high dose infusional
fluorouracil (5-FU) with high dose cisplatin, or the use of a high dose, every 3 week
schedule of cisplatin and paclitaxel. This chemotherapy was combined with a twice daily
hyperfractionated schedule of radiotherapy. Both of these approaches are likely to increase
short-term toxicities of chemoradiotherapy. Hyperfractionated radiotherapy consistently
results in more acute radiation related toxicities than once daily fractionation in many
studies,4–6 and such a dose and schedule of radiotherapy has neither been compared with,
nor shown to be superior to, once daily fractionation. In addition, chemotherapy schedules
employing lower dose, weekly administration of chemotherapy, as opposed to high dose
chemotherapy administered weeks 1 and weeks 3 to 5, also tend to lessen acute toxicities
of chemoradiotherapy.7,8 Phase II trials employing weekly chemotherapy without 5-FU
have reported potentially lower rates of esophagitis, lesser need for the placement of
feeding tubes, and often less hematologic toxicity. Whether or not alternative chemother-
apy or radiotherapy schedules would impact on the development of late onset toxicities,
such as pleural and pericardial effusions, is unclear. Cooperative groups including Eastern
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Group B are exploring weekly chemotherapy regimens with-
out traditional infusional 5-FU, based on phase II trials
indicating favorable rates of GI and hematologic toxicities
with these alternative regimens.
Chemoradiotherapy as a preoperative approach in
esophageal cancer is likely here to stay. Progress, however,
clearly needs to be made with the evaluation of novel sys-
temic agents, including targeted therapies, given the limited
benefit of currently available therapy. Drugs targeting the
epidermal growth factor receptor, including Cetuximab, and
the vascular endothelial growth factor receptor, including
Bevacizumab, are now in active phase II and III clinical trials
in combined modality therapy in esophageal cancer.
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